6-(4-(tert-pentyl)phenoxy)nicotinic acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-(4-(tert-pentyl)phenoxy)nicotinic acid
• 英文别名: 6-[4-(2-methylbutan-2-yl)phenoxy]pyridine-3-carboxylic acid
• 化学式: C₁₇H₁₉NO₃
• 分子量: 285.343
• InChiKey: LTEOINYXBFJBCZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  59.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  ethyl 6-(4-(tert-pentyl)phenoxy)nicotinate 在 水 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 6.5h， 以100%的产率得到6-(4-(tert-pentyl)phenoxy)nicotinic acid
  参考文献：
  名称：

  [EN] ENHANCERS OF NOTCH SIGNALING AND THEIR USE IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH
  [FR] ACTIVATEURS DE SIGNALISATION NOTCH ET LEUR UTILISATION DANS LE TRAITEMENT DE CANCERS ET DE MALIGNITÉS GUÉRISSABLES PAR RÉGULATION À LA HAUSSE DE NOTCH

  摘要：

  本发明涉及使用一种具有通式（I）和/或其药学上可接受的盐或酯的化合物，增强个体中的Notch信号传导，用于治疗选自皮肤病学疾病组的疾病，包括特应性皮炎、银屑病、免疫相关疾病、癌症、鳞状细胞癌、皮肤和肺鳞状细胞癌、头颈癌、非黑色素皮肤癌、基底细胞癌和日光性角化症、神经内分泌肿瘤、神经内分泌小细胞癌和类癌瘤、甲状腺癌、肌肉疾病肌萎缩和损伤后再生能力受损；用于癌症免疫治疗。

  公开号：

  WO2017158190A1

文献信息

• Enhancers of Notch signaling and the use thereof in the treatment of cancers and malignancies medicable by upregulation of Notch
  申请人：XENIOPRO GmbH

  公开号：US10772876B2

  公开（公告）日：2020-09-15

  The present invention relates to the use for enhancing Notch signaling in an individual, of a compound showing the general formula (I) and/or a pharmaceutically acceptable salt or ester thereof, for the treatment of a disease selected from the group of dermatological disorders including atopic dermatitis, psoriasis, immune related disorders, cancer, squamous cell carcinoma, cutaneous and lung squamous cell carcinoma, head and neck cancer, non-melanoma skin cancer, basal cell carcinoma and actinic keratosis, neuroendocrine tumors, neuroendocrine small cell carcinoma and carcinoid tumors, thyroid carcinomas, muscular disorders muscular dystrophy and impaired regeneration capacity after injury; use in immunotherapy for cancer.

  本发明涉及显示通式(I)的化合物和/或其药学上可接受的盐或酯在个体中增强Notch信号转导的用途，用于治疗选自皮肤病组的疾病，包括特应性皮炎、银屑病、免疫相关疾病、癌症、鳞状细胞癌、皮肤鳞状细胞癌和肺鳞状细胞癌、头颈癌、非黑色素瘤皮肤癌、基底细胞癌和光化性角化病、神经内分泌肿瘤、神经内分泌小细胞癌和类癌、甲状腺癌、肌肉疾病肌肉萎缩症和损伤后再生能力受损；用于癌症免疫疗法。
• ENHANCERS OF NOTCH SIGNALING AND THE USE THEREOF IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH
  申请人：XENIOPRO GmbH

  公开号：US20190083476A1

  公开（公告）日：2019-03-21

  The present invention relates to the use for enhancing Notch signaling in an individual, of a compound showing the general formula (I) and/or a pharmaceutically acceptable salt or ester thereof, for the treatment of a disease selected from the group of dermatological disorders including atopic dermatitis, psoriasis, immune related disorders, cancer, squamous cell carcinoma, cutaneous and lung squamous cell carcinoma, head and neck cancer, non-melanoma skin cancer, basal cell carcinoma and actinic keratosis, neuroendocrine tumors, neuroendocrine small cell carcinoma and carcinoid tumors, thyroid carcinomas, muscular disorders muscular dystrophy and impaired regeneration capacity after injury; use in immunotherapy for cancer.
• ENHANCERS OF NOTCH SIGNALING AND THEIR USE THEREOF IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH
  申请人：XENIOPRO GmbH

  公开号：US20200360355A1

  公开（公告）日：2020-11-19

  The present invention relates to the use for enhancing Notch signaling in an individual, of a compound showing the general formula (I) and/or a pharmaceutically acceptable salt or ester thereof, for the treatment of a disease selected from the group of dermatological disorders including atopic dermatitis, psoriasis, immune related disorders, cancer, squamous cell carcinoma, cutaneous and lung squamous cell carcinoma, head and neck cancer, non-melanoma skin cancer, basal cell carcinoma and actinic keratosis, neuroendocrine tumors, neuroendocrine small cell carcinoma and carcinoid tumors, thyroid carcinomas, muscular disorders muscular dystrophy and impaired regeneration capacity after injury; use in immunotherapy for cancer.
• [EN] ENHANCERS OF NOTCH SIGNALING AND THEIR USE IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH<br/>[FR] ACTIVATEURS DE SIGNALISATION NOTCH ET LEUR UTILISATION DANS LE TRAITEMENT DE CANCERS ET DE MALIGNITÉS GUÉRISSABLES PAR RÉGULATION À LA HAUSSE DE NOTCH
  申请人：ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL)

  公开号：WO2017158190A1

  公开（公告）日：2017-09-21

  The present invention relates to the use for enhancing Notch signaling in an individual, of a compound showing the general formula (I) and/or a pharmaceutically acceptable salt or ester thereof, for the treatment of a disease selected from the group of dermatological disorders including atopic dermatitis, psoriasis, immune related disorders, cancer, squamous cell carcinoma, cutaneous and lung squamous cell carcinoma, head and neck cancer, non-melanoma skin cancer, basal cell carcinoma and actinic keratosis, neuroendocrine tumors, neuroendocrine small cell carcinoma and carcinoid tumors, thyroid carcinomas, muscular disorders muscular dystrophy and impaired regeneration capacity after injury; use in immunotherapy for cancer.

  本发明涉及使用一种具有通式（I）和/或其药学上可接受的盐或酯的化合物，增强个体中的Notch信号传导，用于治疗选自皮肤病学疾病组的疾病，包括特应性皮炎、银屑病、免疫相关疾病、癌症、鳞状细胞癌、皮肤和肺鳞状细胞癌、头颈癌、非黑色素皮肤癌、基底细胞癌和日光性角化症、神经内分泌肿瘤、神经内分泌小细胞癌和类癌瘤、甲状腺癌、肌肉疾病肌萎缩和损伤后再生能力受损；用于癌症免疫治疗。